{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:02:52Z","timestamp":1792814572471,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["Allied Health Kidney Research Grant #973281"],"award-info":[{"award-number":["Allied Health Kidney Research Grant #973281"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["Kidney Health Research Grant #856581"],"award-info":[{"award-number":["Kidney Health Research Grant #856581"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40262-026-01632-6","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:48:49Z","timestamp":1774334929000},"page":"731-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic Modelling of Unbound Mycophenolic Acid and its Glucuronide in Adult Kidney Transplant Recipients in Early Post-Transplant"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-6958","authenticated-orcid":false,"given":"Yan","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1938-0801","authenticated-orcid":false,"given":"Ala\u2019A","family":"Al-Dajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0251-6375","authenticated-orcid":false,"given":"Jinal","family":"Adhiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5228-0030","authenticated-orcid":false,"given":"Puja","family":"Dhungana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6350-5258","authenticated-orcid":false,"given":"Patrick","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-4760","authenticated-orcid":false,"given":"Penny","family":"Colbourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-895X","authenticated-orcid":false,"given":"Sita","family":"Gourishankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-9746","authenticated-orcid":false,"given":"Tony K. L.","family":"Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"1632_CR1","unstructured":"The IUPHAR\/BPS Guide to PHARMACOLOGY (IMPDH2). 2025; Available from: https:\/\/www.guidetopharmacology.org\/GRAC\/ObjectDisplayForward?objectId=2625"},{"key":"1632_CR2","first-page":"205","volume-title":"Clinical pharmacokinetics","author":"TK Kiang","year":"2017","unstructured":"Kiang TK, Ensom MH. Anti-rejection drugs. In: Murphy JE, editor. Clinical pharmacokinetics. 6th ed. Bethesda: American Society of Health-System Pharmacists; 2017. p. 205\u201320.","edition":"6"},{"key":"1632_CR3","first-page":"320","volume-title":"Basic clinical pharmacokinetics","author":"TK Kiang","year":"2017","unstructured":"Kiang TK, Ensom MH. Immunosuppressants. In: Beringer, editor. Basic clinical pharmacokinetics. Philadelphia: Wolters Kluwer; 2017. p. 320\u201358."},{"issue":"2","key":"1632_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43(2):150\u2013200. https:\/\/doi.org\/10.1097\/FTD.0000000000000871.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1632_CR5","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1080\/17425255.2021.2027906","volume":"17","author":"Y Rong","year":"2022","unstructured":"Rong Y, Patel V, Kiang TKL. Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects. Expert Opin Drug Metab Toxicol. 2022;17(12):1369\u2013406. https:\/\/doi.org\/10.1080\/17425255.2021.2027906.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1632_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13\u201358. https:\/\/doi.org\/10.2165\/00003088-200746010-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1632_CR7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","volume":"88","author":"CE Staatz","year":"2014","unstructured":"Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88(7):1351\u201389. https:\/\/doi.org\/10.1007\/s00204-014-1247-1.","journal-title":"Arch Toxicol"},{"issue":"6","key":"1632_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","volume":"36","author":"BC de Winter","year":"2009","unstructured":"de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009;36(6):541\u201364. https:\/\/doi.org\/10.1007\/s10928-009-9136-6.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"1632_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jcph.1565","volume":"60","author":"J Benjanuwattra","year":"2020","unstructured":"Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications. J Clin Pharmacol. 2020;60(3):295\u2013311. https:\/\/doi.org\/10.1002\/jcph.1565.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1632_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","volume":"50","author":"CM Sherwin","year":"2011","unstructured":"Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1\u201324. https:\/\/doi.org\/10.2165\/11536640-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1632_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40262-017-0593-6","volume":"57","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547\u201358. https:\/\/doi.org\/10.1007\/s40262-017-0593-6.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1632_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s40262-019-00802-z","volume":"58","author":"TKL Kiang","year":"2019","unstructured":"Kiang TKL, Ensom MHH. Exposure-toxicity relationships of mycophenolic acid in adult kidney transplant patients. Clin Pharmacokinet. 2019;58(12):1533\u201352. https:\/\/doi.org\/10.1007\/s40262-019-00802-z.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1632_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2125.2004.02235.x","volume":"59","author":"BA Atcheson","year":"2005","unstructured":"Atcheson BA, Taylor PJ, Mudge DW, Johnson DW, Hawley CM, Campbell SB, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59(3):271\u201380. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02235.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1632_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/00007890-199804270-00019","volume":"65","author":"B Kaplan","year":"1998","unstructured":"Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65(8):1127\u20139. https:\/\/doi.org\/10.1097\/00007890-199804270-00019.","journal-title":"Transplantation"},{"issue":"3","key":"1632_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1681\/ASN.V133759","volume":"13","author":"LT Weber","year":"2002","unstructured":"Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13(3):759\u201368. https:\/\/doi.org\/10.1681\/ASN.V133759.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1632_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clpt.2005.08.009","volume":"78","author":"P Jacobson","year":"2005","unstructured":"Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005;78(5):486\u2013500. https:\/\/doi.org\/10.1016\/j.clpt.2005.08.009.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1632_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2125.2012.04372.x","volume":"75","author":"A Frymoyer","year":"2013","unstructured":"Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013;75(2):463\u201375. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04372.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1632_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1517\/17425255.2016.1170806","volume":"12","author":"TK Kiang","year":"2016","unstructured":"Kiang TK, Ensom MH. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update. Expert Opin Drug Metab Toxicol. 2016;12(5):545\u201353. https:\/\/doi.org\/10.1517\/17425255.2016.1170806.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"1632_CR19","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","volume":"103","author":"DK Metz","year":"2019","unstructured":"Metz DK, Holford N, Kausman JY, Walker A, Cranswick N, Staatz CE, et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation. 2019;103(10):2012\u201330. https:\/\/doi.org\/10.1097\/TP.0000000000002762.","journal-title":"Transplantation"},{"issue":"2","key":"1632_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/cpt.3206","volume":"116","author":"C Villeneuve","year":"2024","unstructured":"Villeneuve C, Humeau A, Monchaud C, Labriffe M, Rerolle JP, Couzi L, et al. Better rejection-free survival at three years in kidney transplant recipients with model-informed precision dosing of mycophenolate mofetil. Clin Pharmacol Ther. 2024;116(2):351\u201362. https:\/\/doi.org\/10.1002\/cpt.3206.","journal-title":"Clin Pharmacol Ther"},{"issue":"2S1","key":"1632_CR21","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.ajt.2024.01.012","volume":"24","author":"KL Lentine","year":"2024","unstructured":"Lentine KL, Smith JM, Lyden GR, Miller JM, Dolan TG, Bradbrook K, et al. OPTN\/SRTR 2022 annual data report: kidney. Am J Transplant. 2024;24(2S1):S19\u2013118. https:\/\/doi.org\/10.1016\/j.ajt.2024.01.012.","journal-title":"Am J Transplant"},{"issue":"1","key":"1632_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14000","volume":"25","author":"AD Raval","year":"2023","unstructured":"Raval AD, Kistler KD, Tang Y, Vincenti F. Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies. Transpl Infect Dis. 2023;25(1):e14000. https:\/\/doi.org\/10.1111\/tid.14000.","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"1632_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","volume":"68","author":"T van Gelder","year":"1999","unstructured":"van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68(2):261\u20136. https:\/\/doi.org\/10.1097\/00007890-199907270-00018.","journal-title":"Transplantation"},{"issue":"6","key":"1632_CR24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.kint.2021.06.036","volume":"100","author":"T van Gelder","year":"2021","unstructured":"van Gelder T. How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. Kidney Int. 2021;100(6):1185\u20139. https:\/\/doi.org\/10.1016\/j.kint.2021.06.036.","journal-title":"Kidney Int"},{"issue":"6","key":"1632_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2125.2006.02841.x","volume":"63","author":"RM van Hest","year":"2007","unstructured":"van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63(6):741\u201352. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02841.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1632_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40262-019-00771-3","volume":"58","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetics of mycophenolic acid co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients. Clin Pharmacokinet. 2019;58(11):1483\u201395. https:\/\/doi.org\/10.1007\/s40262-019-00771-3.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1632_CR27","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/j.1600-6143.2009.02699.x","volume":"9","author":"L Zafrani","year":"2009","unstructured":"Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant. 2009;9(8):1816\u201325. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02699.x.","journal-title":"Am J Transplant"},{"issue":"4","key":"1632_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/TP.0000000000000444","volume":"99","author":"MA McAdams-DeMarco","year":"2015","unstructured":"McAdams-DeMarco MA, Law A, Tan J, Delp C, King EA, Orandi B, et al. Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients. Transplantation. 2015;99(4):805\u201310. https:\/\/doi.org\/10.1097\/TP.0000000000000444.","journal-title":"Transplantation"},{"issue":"10","key":"1632_CR29","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1016\/j.transproceed.2014.09.107","volume":"46","author":"SM Ji","year":"2014","unstructured":"Ji SM, Xie KN, Chen JS, Wen JQ, Cheng DR, Li X, et al. Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results. Transplant Proc. 2014;46(10):3383\u20139. https:\/\/doi.org\/10.1016\/j.transproceed.2014.09.107.","journal-title":"Transplant Proc"},{"issue":"8","key":"1632_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/tri.12133","volume":"26","author":"T Vanhove","year":"2013","unstructured":"Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, et al. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int. 2013;26(8):813\u201321. https:\/\/doi.org\/10.1111\/tri.12133.","journal-title":"Transpl Int"},{"issue":"6","key":"1632_CR31","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00769-z","volume":"24","author":"R Jelliffe","year":"2022","unstructured":"Jelliffe R, Liu J, Drusano GL, Martinez MN. Individualized patient care through model-informed precision dosing: reflections on training future practitioners. AAPS J. 2022;24(6):117. https:\/\/doi.org\/10.1208\/s12248-022-00769-z.","journal-title":"AAPS J"},{"key":"1632_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001377","author":"M Labriffe","year":"2025","unstructured":"Labriffe M, Sayadi H, Woillard JB, Micallef L, Saint-Marcoux F, Destere A, et al. Large-scale real-world monitoring of mycophenolic acid exposure in liver transplantation: Impact of bayesian dose adjustment. Ther Drug Monit. 2025. https:\/\/doi.org\/10.1097\/FTD.0000000000001377.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1632_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jac\/dkaf007","volume":"80","author":"D Haefliger","year":"2025","unstructured":"Haefliger D, Mina L, Guidi M, Marzolini C, Thoueille P, Rothuizen LE, et al. Individualization of piperacillin dosage based on therapeutic drug monitoring with or without model-informed precision dosing: a scenario analysis. J Antimicrob Chemother. 2025;80(3):840\u20137. https:\/\/doi.org\/10.1093\/jac\/dkaf007.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1632_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40262-017-0603-8","volume":"57","author":"H Colom","year":"2018","unstructured":"Colom H, Andreu F, van Gelder T, Hesselink DA, de Winter BCM, Bestard O, et al. Prediction of free from total mycophenolic acid concentrations in stable renal transplant patients: a population-based approach. Clin Pharmacokinet. 2018;57(7):877\u201393. https:\/\/doi.org\/10.1007\/s40262-017-0603-8.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1632_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/FTD.0b013e3181e6b54d","volume":"32","author":"BA Guillet","year":"2010","unstructured":"Guillet BA, Simon NS, Purgus R, Botta C, Morange S, Berland Y, et al. Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. Ther Drug Monit. 2010;32(4):427\u201332. https:\/\/doi.org\/10.1097\/FTD.0b013e3181e6b54d.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1632_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.1064","volume":"58","author":"M Okour","year":"2018","unstructured":"Okour M, Jacobson PA, Ahmed MA, Israni AK, Brundage RC. Mycophenolic acid and its metabolites in kidney transplant recipients: a semimechanistic enterohepatic circulation model to improve estimating exposure. J Clin Pharmacol. 2018;58(5):628\u201339. https:\/\/doi.org\/10.1002\/jcph.1064.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1632_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40268-020-00319-y","volume":"20","author":"F Riglet","year":"2020","unstructured":"Riglet F, Bertrand J, Barrail-Tran A, Verstuyft C, Michelon H, Benech H, et al. Population pharmacokinetic model of plasma and cellular mycophenolic acid in kidney transplant patients from the CIMTRE study. Drugs R D. 2020;20(4):331\u201342. https:\/\/doi.org\/10.1007\/s40268-020-00319-y.","journal-title":"Drugs R D"},{"key":"1632_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00340","volume":"11","author":"C Sheng","year":"2020","unstructured":"Sheng C, Zhao Q, Niu W, Qiu X, Zhang M, Jiao Z. Effect of protein binding on exposure of unbound and total mycophenolic acid: a population pharmacokinetic analysis in Chinese adult kidney transplant recipients. Front Pharmacol. 2020;11:340. https:\/\/doi.org\/10.3389\/fphar.2020.00340.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1632_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/11312600-000000000-00000","volume":"48","author":"RM van Hest","year":"2009","unstructured":"van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009;48(7):463\u201376. https:\/\/doi.org\/10.2165\/11312600-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1632_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40261-022-01121-1","volume":"42","author":"Y Rong","year":"2022","unstructured":"Rong Y, Colbourne P, Gourishankar S, Kiang TKL. Significant correlations between p-cresol sulfate and mycophenolic acid plasma concentrations in adult kidney transplant recipients. Clin Drug Investig. 2022;42(3):207\u201319. https:\/\/doi.org\/10.1007\/s40261-022-01121-1.","journal-title":"Clin Drug Investig"},{"key":"1632_CR41","unstructured":"Lixoft. Monolix Suite 2024R1 - Monolix. 2025; Available from: https:\/\/monolixsuite.slp-software.com\/monolix\/2024R1\/"},{"key":"1632_CR42","unstructured":"PubChem. 2025; Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/"},{"issue":"3","key":"1632_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s13318-018-0525-3","volume":"44","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetic analysis of immediate-release oral tacrolimus co-administered with mycophenolate mofetil in corticosteroid-free adult kidney transplant recipients. Eur J Drug Metab Pharmacokinet. 2019;44(3):409\u201322. https:\/\/doi.org\/10.1007\/s13318-018-0525-3.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"1632_CR44","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40262-023-01280-0","volume":"62","author":"Y Rong","year":"2023","unstructured":"Rong Y, Wichart J, Hamiwka L, Kiang TKL. Significant effects of renal function on mycophenolic acid total clearance in pediatric kidney transplant recipients with population pharmacokinetic modeling. Clin Pharmacokinet. 2023;62(9):1289\u2013303. https:\/\/doi.org\/10.1007\/s40262-023-01280-0.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1632_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40268-020-00323-2","volume":"20","author":"H Jun","year":"2020","unstructured":"Jun H, Rong Y, Yih C, Ho J, Cheng W, Kiang TKL. Comparisons of four protein-binding models characterizing the pharmacokinetics of unbound phenytoin in adult patients using non-linear mixed-effects modeling. Drugs R D. 2020;20(4):343\u201358. https:\/\/doi.org\/10.1007\/s40268-020-00323-2.","journal-title":"Drugs R D"},{"issue":"8","key":"1632_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/11634080-000000000-00000","volume":"51","author":"TK Kiang","year":"2012","unstructured":"Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51(8):515\u201325. https:\/\/doi.org\/10.2165\/11634080-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1632_CR47","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF03261932","volume":"51","author":"CM Sherwin","year":"2012","unstructured":"Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573\u201390. https:\/\/doi.org\/10.1007\/BF03261932.","journal-title":"Clin Pharmacokinet"},{"key":"1632_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet Syst Pharmacol. 2012;1:e6. https:\/\/doi.org\/10.1038\/psp.2012.4.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"10","key":"1632_CR49","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1345\/aph.1D374","volume":"38","author":"EI Ette","year":"2004","unstructured":"Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38(10):1702\u20136. https:\/\/doi.org\/10.1345\/aph.1D374.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1632_CR50","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1345\/aph.1E259","volume":"38","author":"EI Ette","year":"2004","unstructured":"Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother. 2004;38(11):1907\u201315. https:\/\/doi.org\/10.1345\/aph.1E259.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1632_CR51","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1345\/aph.1E260","volume":"38","author":"EI Ette","year":"2004","unstructured":"Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother. 2004;38(12):2136\u201344. https:\/\/doi.org\/10.1345\/aph.1E260.","journal-title":"Ann Pharmacother"},{"key":"1632_CR52","unstructured":"Lixoft. Monolix \u201cProposal\u201d Function. 2025; Available from: https:\/\/monolixsuite.slp-software.com\/monolix\/2024R1\/proposal"},{"key":"1632_CR53","unstructured":"Lixoft. Monolix Suite 2024R1 - Simulx. 2025; Available from: https:\/\/monolixsuite.slp-software.com\/simulx\/2024R1\/"},{"key":"1632_CR54","unstructured":"GraphPad Prism software. 2025; Available from: https:\/\/www.graphpad.com\/scientific-software\/prism\/"},{"issue":"4","key":"1632_CR55","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/bcp.14590","volume":"87","author":"Y Rong","year":"2021","unstructured":"Rong Y, Jun H, Kiang TKL. Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol. 2021;87(4):1730\u201357. https:\/\/doi.org\/10.1111\/bcp.14590.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1632_CR56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1632_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3177\/jnsv.53.37","volume":"53","author":"I Gom","year":"2007","unstructured":"Gom I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K, et al. Relationship between serum albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci Vitaminol (Tokyo). 2007;53(1):37\u201342. https:\/\/doi.org\/10.3177\/jnsv.53.37.","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"issue":"Pt 1","key":"1632_CR58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/0004563215593561","volume":"53","author":"G Weaving","year":"2016","unstructured":"Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem. 2016;53(Pt 1):106\u201311. https:\/\/doi.org\/10.1177\/0004563215593561.","journal-title":"Ann Clin Biochem"},{"key":"1632_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911675","author":"FHC Tsao","year":"2022","unstructured":"Tsao FHC, Meyer KC. Human serum albumin misfolding in aging and disease. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911675.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1632_CR60","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.neuroimage.2010.12.032","volume":"55","author":"JJ Chen","year":"2011","unstructured":"Chen JJ, Rosas HD, Salat DH. Age-associated reductions in cerebral blood flow are independent from regional atrophy. Neuroimage. 2011;55(2):468\u201378. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.12.032.","journal-title":"Neuroimage"},{"issue":"4","key":"1632_CR61","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","volume":"17","author":"JR Weinstein","year":"2010","unstructured":"Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302\u20137. https:\/\/doi.org\/10.1053\/j.ackd.2010.05.002.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"1632_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ageing\/28.1.29","volume":"28","author":"M Zoli","year":"1999","unstructured":"Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing. 1999;28(1):29\u201333. https:\/\/doi.org\/10.1093\/ageing\/28.1.29.","journal-title":"Age Ageing"},{"issue":"3","key":"1632_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/cld.894","volume":"15","author":"FQ Onofrio","year":"2020","unstructured":"Onofrio FQ, Hirschfield GM. The pathophysiology of cholestasis and its relevance to clinical practice. Clin Liver Dis. 2020;15(3):110\u20134. https:\/\/doi.org\/10.1002\/cld.894.","journal-title":"Clin Liver Dis"},{"issue":"3","key":"1632_CR64","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/j.1552-4604.1998.tb04424.x","volume":"38","author":"LM Shaw","year":"1998","unstructured":"Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38(3):268\u201375. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04424.x.","journal-title":"J Clin Pharmacol"},{"key":"1632_CR65","unstructured":"The IUPHAR\/BPS Guide to Pharmacology (IMPDH1). 2025; Available from: https:\/\/www.guidetopharmacology.org\/GRAC\/ObjectDisplayForward?objectId=2624"},{"issue":"11","key":"1632_CR66","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40261-018-0694-5","volume":"38","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Partovi N, Shapiro RJ, Berman JM, Collier AC, Ensom MHH. Regression and genomic analyses on the association between dose-normalized mycophenolic acid exposure and absolute neutrophil count in steroid-free, de novo kidney transplant recipients. Clin Drug Investig. 2018;38(11):1011\u201322. https:\/\/doi.org\/10.1007\/s40261-018-0694-5.","journal-title":"Clin Drug Investig"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01632-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:50:39Z","timestamp":1779119439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01632-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01632-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We acknowledge the grant supports from the Kidney Foundation of Canada (Allied Health Kidney Research Grant #973281 and Kidney Health Research Grant #856581 [Principal Investigator on both grants: Tony Kiang]).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interests pertaining to the preparation of this manuscript. Dr Tony Kiang serves on the editorial board of\n                      Clinical Pharmacokinetics\n                      but was not involved in any editorial process related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"Data available on reasonable request to the corresponding author due to privacy\/ethical restrictions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"This project received ethics approval from the University of Alberta Research Ethics Boards (study ID Pro00113219 and Pro00121659), which followed the Declaration of Helsinki principles.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written consents to participate were obtained per our ethics protocols (study ID Pro00113219 and Pro00121659).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consents to publish were obtained per our ethics protocols (study ID Pro00113219 and Pro00121659).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Research project conception: Tony Kiang; Patient consent, sample collection, clinical data collection: Ala\u2019A Al-Dajani, Jinal Adhiya, Puja Dhungana, Yan Rong; Sample analyses: Ala\u2019A Al-Dajani and Jinal Adhiya; PopPK modelling and simulation: Tony Kiang, Yan Rong, Ala\u2019A Al-Dajani, Patrick Mayo; Data interpretation: Tony Kiang, Yan Rong, Penny Colbourne, Sita Gourishankar; Manuscript preparation: Yan Rong and Tony Kiang; Manuscript editing and approval for submission: All listed authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}